Oxurion NV Announces the Passing of Dr. Claude Sander, Chief Legal Officer and Corporate Secretary to the Board décembre 21, 20190CommentsEN Read More
Oxurion NV to Focus Clinical Development on Molecules Targeting VEGF Independent Pathways for Treatment of DME décembre 19, 20190CommentsEN Read More
Oxurion NV to Provide Business and Clinical Update at Upcoming American Academy of Ophthalmology annual meeting (AAO) and Ophthalmology Innovation Summit (OIS @AAO) in San Francisco octobre 9, 20190CommentsEN Read More
Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a novel, potent plasma kallikrein inhibitor for DME septembre 9, 20190CommentsEN Read More
Oxurion Completes Enrollment of Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for the Treatment of Diabetic Macular Edema (DME) septembre 4, 20190CommentsEN Read More
Oxurion to make a late-breaker presentation of topline THR-149 (Plasma Kallikrein inhibitor) Phase 1 clinical data at EURETINA 2019 septembre 2, 20190CommentsEN Read More
Oxurion NV Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 (anti-PLGF), in Combination with Ranibizumab, for DME août 20, 20190CommentsEN Read More
Oxurion NV Reports Positive Topline Phase 1 Results with THR-149, a novel, potent plasma kallikrein inhibitor for the treatment of DME juillet 1, 20190CommentsEN Read More
Tussentijds verslag – Halfjaarcijfers per 30 juni 2019 juin 30, 20190CommentsTussentijds verslag - Halfjaarcijfers per 30 juni 2019 Read More
Interim Financial Report – Half-year results as of June 30, 2019 juin 30, 20190CommentsInterim Financial Report - Half-year results as of June 30, 2019 Read More
ONCURIOUS NV Receives Project Grant from VLAIO to Progress its Pipeline of Next Generation Cancer Immunotherapies juin 11, 20190CommentsEN Read More
Oxurion NV – Data from Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for DME presented at 2019 FLORetina Meeting juin 6, 20190CommentsEN Read More
Oxurion NV to Present Further Preclinical Data at 2019 ARVO Meeting avril 26, 20190CommentsEN Read More
Oxurion NV announces full enrollment in Phase 1 trial evaluating the safety of plasma kallikrein inhibitor THR-149 for treatment of DME, ahead of schedule avril 24, 20190CommentsEN Read More
Oxurion NV announces full enrollment of its Phase 2 trial evaluating efficacy and safety of the combination of anti-PlGF (THR-317) and anti-VEGF (ranibizumab) for the treatment of DME, ahead of schedule avril 4, 20190CommentsEN Read More
